Regional chest wall volumes during exercise in chronic obstructive pulmonary disease

A Aliverti, N Stevenson, R L DELLACA, A Lo Mauro, A Pedotti, P M A Calverley

Background: Dynamic hyperinflation of the lungs impairs exercise performance in chronic obstructive pulmonary disease (COPD). However, it is unclear which patients are affected by dynamic hyperinflation and how the respiratory muscles respond to the change in lung volume.

Methods: Using optoelectronic plethysmography, total and regional chest wall volumes were measured non-invasively in 20 stable patients with COPD (mean (SD) forced expiratory volume in 1 second 43.6 (11.6)% predicted) and dynamic hyperinflation was tracked breath by breath to test if this was the mechanism of exercise limitation. Resting ventilation, breathing pattern, symptoms, rib cage and abdominal volumes were recorded at rest and during symptom limited cycle ergometry. Pleural, abdominal, and transdiaphragmatic pressures were measured in eight patients.

Results: End expiratory chest wall volume increased by a mean (SE) of 592 (80) ml in 12 patients (hyperinflators) but decreased by 462 (103) ml in eight (euvolumics). During exercise, tidal volume increased in euvolumic patients by reducing end expiratory abdominal volume while in hyperinflators tidal volume increased by increasing end inspiratory abdominal and rib cage volumes. The maximal abdominal pressure was 22.1 (9.0) cm H2O in euvolumic patients and 7.6 (2.6) cm H2O in hyperinflators. Euvolumic patients were as breathless as hyperinflators but exercised for less time and reached lower maximum workloads (p<0.05) despite having better spirometric parameters and a greater expiratory flow reserve.

Conclusions: Dynamic hyperinflation is not the only mechanism limiting exercise performance in patients with stable COPD. Accurate measurement of chest wall volume can identify the different patterns of respiratory muscle activation during exercise.

Exercise limitation is a major cause of disability in patients with chronic obstructive pulmonary disease (COPD) and is largely the result of disturbances in the mechanics of breathing. Tests of airflow limitation at rest such as forced expiratory volume in 1 second (FEV1) are relatively poor predictors of exercise duration in these patients. The most common explanation for this is that, unlike healthy subjects, end expiratory lung volume (EELV) increases during exercise in patients with COPD, decreasing the inspiratory capacity (IC). This dynamic hyperinflation increases the ability of the respiratory system to generate expiratory flow but limits the maximum tidal volume and reduces the ability of inspiratory muscles to produce force by reducing their length, leading to the sensation of breathlessness. At present few data are available on the time course of these changes, how the volume change is distributed between the compartments of the chest wall (ribs cage and abdomen), and what happens in patients who do not show these changes in lung volume.

EELV is usually measured indirectly from IC, but this is influenced by the subject’s ability to cooperate. It cannot follow breath-to-breath variation in lung volume. Integrator drift, which is multifactorial in origin, also poses a problem. This problem can be overcome by using optoelectronic plethysmography (OEP). OEP is an accurate non-invasive method for measuring total chest wall volume (Vcw), ventilation, and respiratory kinematics. It enables analysis of chest wall motion and accurately measures changes in the volume of the different respiratory compartments of the chest wall in different postures and conditions. Although OEP cannot measure the absolute lung volume unless the subdivisions of lung volume are also known, it can measure changes in volume such as during a tidal breath and can record breath by breath changes in EELV, as well as its distribution between the different chest wall compartments.*

A study was undertaken to measure operating chest wall volumes on a breath by breath basis in patients with clinically stable symptomatic COPD at rest and during exercise, and thus to assess how the chest wall changed as dynamic hyperinflation developed. We hypothesised that an increase in end expiratory Vcw would be the most important factor limiting exercise, but found a more complex situation than we anticipated.

METHODS

Subjects

Twenty men with stable COPD diagnosed by accepted criteria took part in the study. All had been smokers and complained of exertional dyspnoea. None had clinical or physiological features of bronchial asthma or a history of exacerbation in the previous 6 weeks. There were no co-morbid conditions limiting exercise. Patients were studied before pulmonary rehabilitation and were unfamiliar with physiological exercise testing. Routine bronchodilator drugs were omitted for 4 hours (short acting) or 12 hours (long acting) before attendance. The

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; EELV, end expiratory lung volume; Vcw, end expiratory chest wall volume; FEF, forced expiratory flow at a percentage of FVC; FEV1, forced expiratory volume in 1 second; FRC, functional residual capacity; FVC, forced vital capacity; IC, inspiratory capacity; OEP, optoelectronic plethysmography; Pab, abdominal pressure; Pdi, transdiaphragmatic pressure; Pga, gastric pressure; Poes, oesophageal pressure; Ppl, pleural pressure; RV, residual volume; TLC, total lung capacity; Vab, abdominal volume; Vcw, total chest wall volume; Vrc, rib cage volume
protocol was approved by the district research ethics committee and informed consent was obtained.

**Measurements**

Subdivisions of lung volumes were measured by body plethysmography (Medgraphic Autolink 1085D, Medical Graphics, St Paul, MN, USA) using ATS standards. Flow was measured at the mouth by a screen pneumotachograph and integrated to display the flow-volume loop from which FEV₁, FVC, and flow indices were derived. 

Chest wall kinematics and compartmental volumes were non-invasively measured by OEP. The principle of this method is described in detail elsewhere. Briefly, OEP measures the change in the complex shape of the chest wall during breathing by modelling the thoracoabdominal surface with a large number of points belonging to selected anatomical reference sites on the rib cage and abdomen. The three dimensional positions and displacements of each point are measured by a motion analyser (BTS, Milan, Italy) based on passive (reflective) markers (plastic hemispheres of 10 mm diameter covered by a thin film of retroreflective paper) placed on the skin using biadhesive hypoallergenic tape and special TV cameras operating up to 100 frames per second synchronised with coaxial infrared flashing LEDs. After computing and classifying the two dimensional coordinates of all markers surveyed by at least two TV cameras, the system determines the three dimensional coordinates of the different markers by stereo-photogrammetry. Once the three dimensional coordinates of the points belonging to the chest wall surface area acquired with reference to an arbitrary coordinate system, a closed surface is defined by connecting the points to form triangles (mesh of triangles) and the volume contained by the surface is computed using Gauss' theorem. This procedure allows the direct computation of the volume enclosed by the thoracoabdominal surface approximated by a closed mesh of triangles. The three dimensional positions and displacements of each point are measured by a motion analyser (BTS, Milan, Italy) synchronised with coaxial infrared flashing LEDs. 

Eight patients were instrumented using standard balloon tipped catheters connected to pressure transducers (SCX05; Sensym, Milpitas, CA, USA) for recording oesophageal (Poes) and gastric (Pga) pressures which were used as indices of pleural (Ppl) and abdominal (Pab) pressures, respectively. Transdiaphragmatic pressure (Pdi) was computed as the difference between Pga and Poes. In these subjects we also continuously measured flow at the airway opening using a low dead space (70 ml) pneumotachograph (Medical Graphics). 

Breath by breath oxygen consumption and carbon dioxide production were measured using a fuel cell and infrared carbon dioxide analyser, respectively, as part of a commercial exercise system (Medical Graphics).

Pressures and flow signals were synchronised to those of the motion analyser used for OEP and sent to a personal computer for subsequent analysis. Oxygen saturation was measured by pulse oximetry (Biox 3700e, Ohmeda, Louisville, CO, USA).

**Protocol**

After performing spirometric and plethysmographic measurements in the body box the subjects were asked to sit on an electrically braked cycle ergometer. Once acclimatised, quiet breathing for 3 minutes and a slow vital capacity to determine chest wall volumes at functional residual capacity (FRC), total lung capacity (TLC), and residual volume (RV) were measured. The patients than began pedalling for 3 min with 10 W increases in workload every subsequent 3 minutes until exhaustion. Data were collected during the last minute of each workload, including the subject’s subjective assessment of breathing difficulty and leg fatigue using a 10 point modified Borg category scale. During both rest and exercise the subjects grasped handles positioned at mid-sternum level, which lifted the arms away from the rib cage, so that lateral markers could be visualised.

**Data analysis**

**Modelling of the chest wall**

The chest wall was modelled as if it was composed of two compartments—rib cage and abdomen. A change in abdominal volume (Vab) was defined as the volume swept by the abdominal wall and the boundary between the rib cage and abdomen along the lower costal margin anteriorly and at the level of the lower point of the lower costal margin posteriorly. Total chest wall volume (Vcw) equalled the sum of rib cage volume (Vrc) and Vab. The pulmonary and abdominal rib cage compartments have been combined as Vrc in this analysis.

**Comparison between chest wall and pneumotachographic volumes**

As in previous studies in which we assessed the ability of OEP to measure changes in lung volume, we compared changes in Vcw during inspiration obtained by OEP (∆Vcw) with inspired volumes obtained by integration of flow (∆Vm), considering the difference between values at the beginning and end of inspiration. For each instrumented patient, 5–6 breaths were studied during both quiet breathing and at their maximal workload during exercise. Data were then compared by linear regression analysis.

**Chest wall, ventilatory pattern and work of breathing**

During quiet breathing and exercise OEP data were used to measure end expiratory and end inspiratory Vrc, Vab, and Vcw and the complete ventilatory pattern (including tidal volume, breathing frequency, minute ventilation, inspiratory and expiratory times) at each workload. All volumes reported are the combined mean values over the last minute of each run (unless otherwise specified). The work of breathing performed on the lung in the instrumented patients was calculated as the area enclosed by the Poes–Vcw loops.

Patients were considered to show dynamic hyperinflation of the chest wall if the end expiratory Vcw increased above its resting value at maximum workload. Those in whom Vcw was maintained or reduced were described as euvolumic. This terminology was the same as that used in other published papers, in which similar patterns of behaviour were found in healthy subjects in response to an incremental exercise test with expiratory flow limitation artificially induced by a Starling resistor.

**Statistical analysis**

Data are presented as mean (SE) unless otherwise stated. Differences between anthropometric, spirometric, and exercise data sets were tested using Wilcoxon and Mann-Whitney tests for paired and unpaired data, respectively, with a 5% significance level. To compare chest wall volumes at end expiration and end inspiration at different workloads between euvolumic and hyperinflator patients we applied a repeated measures analysis of variance (ANOVA). This enabled us to test for an overall difference between workloads (within-subject effect) and between groups (euvolumics v hyperinflators). When ANOVA was significant, post hoc Fisher's PLSD test was performed to verify the statistical significance of the differences between pairs of means. For all tests the significance level was taken as p<0.05.

**RESULTS**

Baseline anthropometric and pulmonary function data are shown in table 1. Instrumentation did not influence exercise performance or the changes in Vcw during exercise.

www.thoraxjnlin.com
Comparison of OEP with pneumotachograph data

The relationship between $\Delta V_{cw}$ (OEP) and $\Delta V_m$ (pneumotachograph) is shown in fig 1. Each data point represents the mean of 10–15 breaths either during quiet breathing or at maximum exercise. The linear regression analysis provided the following equation: $\Delta V_{cw} = 1.12 \cdot \Delta V_m - 0.08$ ($r^2 = 0.92, p<0.0001$). Using the same data, the mean (SE) percentage difference between $\Delta V_m$ and $\Delta V_{cw}$ (computed as $(\Delta V_m - \Delta V_{cw})/\Delta V_m \times 100$) was $-4.3 (2.5)\%$. When only quiet breathing data were considered the equation was $\Delta V_{cw} = 1.16 \cdot \Delta V_m + 0.17 (r^2 = 0.933, p<0.001)$ with a mean (SE) percentage difference of $0.8 (3.2)\%$; when only exercise data were considered the equation was $\Delta V_{cw} = 0.95 \cdot \Delta V_m - 0.15 (r^2 = 0.92, p<0.001)$ with a mean (SE) percentage difference of $-9.5 (2.9)\%$. At rest $\Delta V_m$ and $\Delta V_{cw}$ differed by 5 (30) ml, while at maximum workload the difference was $-100 (29)$ ml, the $\Delta V_{cw}$ values being larger.

Changes in end expiratory chest wall volume during exercise

Two patterns of change in $V_{cw}$ occurred during exercise. End expiratory $V_{cw}$ increased by a mean (SE) of 592 (80) ml in the euvolumic group (three instrumented; fig 2, right hand panels). End expiratory $V_r$ increased significantly by 494 (90) ml in the hyperinflated patients compared with 46 (148) ml in the euvolumic group (p<0.05) during unloaded cycling and remained constant thereafter. End expiratory Vab remained constant in hyperinflators throughout exercise with the end inspiratory volumes rising to accommodate the increases in $V_r$ (fig 2, left hand and middle panels). In euvolumic patients the end expiratory Vab was reduced at the onset of exercise and remained constant thereafter. The right hand panel of fig 2 shows that the change in $V_{cw}$ (that is, the tidal volume) in these patients was almost entirely the result of the decrease in Vab while end inspiratory $V_{cw}$ remained almost constant. In contrast, the hyperinflators end inspiatory $V_{cw}$ approached the TLC values measured before exercise and this was accomplished by increases in both $V_r$ and Vab.

Resting lung volumes including IC were not significantly different between the exercise groups nor was the degree of oxygen desaturation during exercise. Both hyperinflator and euvolumic patients reported a similar degree of breathlessness and leg effort scored at peak exercise. However, euvolumic patients had significantly higher BMI, pre-exercise $FEV_1$, $FEV_1/FVC$ ratio, and forced expiratory flows at 25% and 50% of expired volume (table 1).

Flow, pressure, and regional volume relationships

Figure 3 shows the flow-volume and compartmental pressure-volume relationships of two representative subjects, one hyperinflator (top panels) and one euvolumic (bottom panels). The hyperinflator had a rightward displacement of the tidal flow-volume loop at peak exercise with an expiratory flow profile that had changed little from that under resting conditions. There was an increase in both rib cage and abdominal volumes with little change in the shape of the pressure-volume loop. In contrast, in the euvolumic patient the expiratory flow was increased during exercise at close to the resting end expiratory volume with marked abdominal muscle pressure generation. This pattern was consistent in all the patients in which it could be assessed.

Exercise capacity, breathing pattern, and respiratory pressures

Although peak exercise ventilation was the same, hyperinflators reached a mean (SE) maximum workload of 35.0 (4.8) watts with an exercise duration of 13.7 (1.4) min, while the euvolumic patients achieved a maximum workload of 20.0 (4.2) watts and an exercise duration of 8.8 (1.3) min (p<0.05). The change in end expiratory $V_{cw}$ was weakly related to the maximum workload achieved ($r^2 = 0.216, p = 0.038$; fig 4).

Tidal volume and frequency at maximum workload were similar in the two groups with no significant difference in the

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Mean (SD) baseline anthropometric and pulmonary function data of study subjects and subgroups defined by their end expiratory lung volumes during exercise</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All (n = 20)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>68.6 (7.0)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.3 (2.8)</td>
</tr>
<tr>
<td>$FEV_1$ (l)</td>
<td>1.28 (0.38)</td>
</tr>
<tr>
<td>$FEV_1$ (%)</td>
<td>43.6 (11.6)</td>
</tr>
<tr>
<td>$FVC$ (%)</td>
<td>73.5 (16.3)</td>
</tr>
<tr>
<td>$FEV_1/FVC$ (%)</td>
<td>46.0 (8.4)</td>
</tr>
<tr>
<td>IC (l)</td>
<td>2.35 (0.44)</td>
</tr>
<tr>
<td>TLC (%)</td>
<td>128.7 (18.7)</td>
</tr>
<tr>
<td>FRC</td>
<td>174.2 (44.1)</td>
</tr>
<tr>
<td>RV (%)</td>
<td>202.9 (59.6)</td>
</tr>
<tr>
<td>$FEF_{25%}$ (%)</td>
<td>19.1 (10.8)</td>
</tr>
<tr>
<td>$FEF_{50%}$ (%)</td>
<td>14.8 (7.0)</td>
</tr>
<tr>
<td>$FEF_{75%}$ (%)</td>
<td>17.6 (5.8)</td>
</tr>
</tbody>
</table>

*p<0.05, hyperinflators v euvolumics.
Chest wall volumes in COPD

Figure 2  Compartmental and total chest wall volume changes in hyperinflating (upper panels, HY) and euvolumic (lower panels, EU) patients. Open circles = end inspiration; closed circles = end expiration. Mean values and standard error bars are shown. \(*p<0.05\), **p<0.01, ***p<0.001 v quiet breathing (QB); \(\text{t}p<0.05\), \(\text{tt}p<0.01\), \(\text{tttt}p<0.001\) hyperinflators (HY) v euvolumics (EU).

In the instrumented patients the mean and peak transdiaphragmatic pressure swings remained relatively constant at rest and during exercise. The mean abdominal pressure swings at maximum exercise were negative in both groups and the maximal abdominal pressures were times three greater in the euvolumics than in the hyperinflators, but the difference was not statistically significant (table 2).

Although resting and peak exercise oxygen consumption were similar in both groups, the calculated work of breathing at the same level of exercise was substantially greater in the euvolumics than in the hyperinflators, but the difference was not statistically significant (table 2).

In their resting expiratory flow reserve. The hyperinflators reached end inspiratory volumes close to their resting TLC while the euvolumic patients had an apparent end inspiratory reserve when they stopped. The change in end expiratory Vrc occurred in hyperinflators before loaded exercise began—a finding previously noted in COPD patients using less quantitative methods—and it did not change further in either group as exercise intensity increased. The effect of exercise on the abdominal compartment was equally distinct with end inspiratory Vab increasing in hyperinflators, while in euvolumic patients the end inspiratory Vab remained constant but higher abdominal pressure developed to try to reduce end expiratory Vab (fig 3).

DISCUSSION

When healthy subjects exercise, end expiratory lung volume falls as ventilation increases—a change seen in young adults and in healthy elderly subjects of a similar age to our patients. Changes in lung volume can be inferred from changes in IC, but the respiratory response to exercise also involves the distribution of these volume changes to different chest wall compartments involving the activity of different groups of respiratory muscles. Initial studies of Vcw in patients with COPD used semi-quantitative methods based on magnetometers and were the first to show that dynamic hyperinflation occurred during exercise in some of these patients.

OEP represents an important technical advance which has allowed us to define how Vcw changes during exercise in patients with COPD. As a result, we have identified two different behaviour patterns in changes to end expiratory Vcw during exercise.

Studies with externally applied flow resistance in healthy subjects showed differences in the pattern of response to exercise, with some maintaining the normal fall in EELV throughout exercise while others allowed EELV to rise before stopping. In most of our COPD patients end expiratory Vcw increased with exercise, but in a significant number the pattern seen in healthy subjects was adopted with reduced Vab preventing dynamic hyperinflation. In each case the response of a particular individual was constant and the differences between groups at each workload were statistically significant (fig 2). The hyperinflators reached end inspiratory volumes close to their resting TLC while the euvolumic patients had an apparent end inspiratory reserve when they stopped. The change in end expiratory Vrc occurred in hyperinflators before loaded exercise began—a finding previously noted in COPD patients using less quantitative methods—and it did not change further in either group as exercise intensity increased. The effect of exercise on the abdominal compartment was equally distinct with end inspiratory Vab increasing in hyperinflators, while in euvolumic patients the end inspiratory Vab remained constant but higher abdominal pressure developed to try to reduce end expiratory Vab (fig 3).

It is not clear why these different responses to exercise occur. The presence of balloon catheters or breathing via a mouthpiece did not explain the pattern observed. All patients had omitted their normal bronchodilator drugs and none had undergone pulmonary rehabilitation, an intervention which can modify changes in lung volume during exercise. There was no difference in the oxygen saturation during exercise and the oxygen consumption, when measured, was similar at equivalent workloads. Although the BMI differed between the groups, this is likely to reflect differences in disease severity, with euvolumic patients having significantly better spirometric parameters. Differences in the relative amounts of emphysema or small airways disease might be relevant, although the presence of emphysema is not necessary for dynamic hyperinflation to occur.

The most likely explanation is a difference between groups in their resting expiratory flow reserve. The hyperinflators reported here are very similar to those reported by O’Donnell and colleagues, exhibiting quantitatively similar changes in end expiratory Vcw using optoelectronic measurement to...
Mean values and standard error bars are shown for the two groups; exercise workload reached by euvolumic and hyperinflator patients.

Figure 4  Relationship between change in end expiratory chest wall volume from quiet breathing to exercise (ΔEEVcw) and maximum exercise workload reached by euvolumic and hyperinflator patients. Mean values and standard error bars are shown for the two groups; *p<0.05.

Those in EELV measured using the IC technique and with similar impairments in resting spirometry and expiratory flow. Data from the composite tidal flow-volume loops in our patients are compatible with the presence of resting tidal flow limitation which is associated with hyperinflation in COPD.23 In contrast, the euvolumic patients were less obstructed and had less marked flow limitation at lung volumes within the resting tidal range, as assessed by their maximum pre-exercise flow-volume loops and the non-invasive data shown in fig 3. Despite their better inspiratory flow reserve, euvolumic patients developed high intra-abdominal pressure rather than permitting EELV to rise as in the hyperinflators.

Whatever the explanation, maintaining a normal end expiratory lung volume is a poor adaptive strategy. The calculated work of breathing at end exercise was substantially higher in the euvolumic patients than in the hyperinflators, confirming that exercise was not limited by poor motivation in this group. The increase in oxygen consumption by the respiratory muscles in euvolumic patients resulting from this increase in work of breathing effectively competes for a larger share of the whole body oxygen consumption, reducing the oxygen available to the leg muscles.23 This may explain why patients who adopted this strategy, although as breathless as hyperinflators when they stopped, exercised for less time and reached a lower intensity of power at equivalent levels of breathlessness.

Measurements of Vcw are normally identical to the volume change recorded at the mouth during spontaneous breathing12 or that measured in ventilated and paralysed patients.13 In our COPD patients there was good overall agreement between the inspiratory tidal volume and Vcw, amounting to an error of 0.8% at rest, equivalent to a difference of 5 ml in the resting tidal volume. This increased to a 9.5% error at maximal exercise, equivalent to a difference
Chest wall volumes in COPD

This work was supported in part by the European Community CARED (contract no QLG5-CT-2002-0893).

Authors’ affiliations
A Aliverti, R L Dellacó, A Lo Mauro, A Pedotti, Dipartimento di Bioingegneria, Politecnico di Milano, Italy
N Stevenson, P M A Calverley, University Department of Medicine, University Hospital Aintree, Liverpool, UK

This work was supported in part by the European Community CARED FPS project (contract no QLG5-CT-2002-0893).

REFERENCE

Table 2 Mean (SE) values of exercise performance, breathing pattern, exercise duration, respiratory pressures, energetics and sensation at rest and maximal exercise (Wmax) for the euvolumic and hyperinflating subjects

<table>
<thead>
<tr>
<th>All</th>
<th>Rest</th>
<th>Wmax</th>
<th>Rest</th>
<th>Wmax</th>
<th>Hyperinflators</th>
<th>Rest</th>
<th>Wmax</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exercise duration (min)</td>
<td>11.8 (1.0)</td>
<td>8.8 (1.3)</td>
<td>13.7 (1.4)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wmax (watt)</td>
<td>29.0 (3.4)</td>
<td>20.0 (4.2)</td>
<td>35.0 (4.8)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breathing frequency (/min)</td>
<td>16.8 (1.0)</td>
<td>27.3 (1.6)</td>
<td>15.1 (0.5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ti (s)</td>
<td>1.47 (0.11)</td>
<td>0.91 (0.06)</td>
<td>1.27 (0.06)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Te (s)</td>
<td>2.41 (0.18)</td>
<td>1.49 (0.19)</td>
<td>2.03 (0.13)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minute ventilation (/min)</td>
<td>12.7 (1.0)</td>
<td>27.3 (2.8)</td>
<td>12.7 (0.9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximum Ppl (cm H2O)</td>
<td>3.5 (1.4)</td>
<td>14.0 (4.6)</td>
<td>4.4 (2.9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximum Pab (cm H2O)</td>
<td>5.8 (1.7)</td>
<td>14.2 (4.6)</td>
<td>6.7 (3.7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Work of breathing (cm H2O-l/min)</td>
<td>1.40 (31)</td>
<td>456 (132)</td>
<td>1.55 (12)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxygen consumption (ml/min)</td>
<td>259 (14)</td>
<td>558 (20)</td>
<td>248 (10)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>86 (5)</td>
<td>104 (3)</td>
<td>95 (6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bloodlessness</td>
<td>0.8 (0.3)</td>
<td>4.8 (0.5)</td>
<td>1.1 (0.5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leg effort</td>
<td>1.6 (0.5)</td>
<td>5.6 (0.5)</td>
<td>3.1 (0.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximum Ppa (cm H2O)</td>
<td>3.5 (1.4)</td>
<td>14.0 (4.6)</td>
<td>4.4 (2.9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximum Ppl (cm H2O)</td>
<td>5.8 (1.7)</td>
<td>14.2 (4.6)</td>
<td>6.7 (3.7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximum Pab (cm H2O)</td>
<td>5.8 (1.7)</td>
<td>14.2 (4.6)</td>
<td>6.7 (3.7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Work of breathing (cm H2O-l/min)</td>
<td>1.40 (31)</td>
<td>456 (132)</td>
<td>1.55 (12)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxygen consumption (ml/min)</td>
<td>259 (14)</td>
<td>558 (20)</td>
<td>248 (10)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>86 (5)</td>
<td>104 (3)</td>
<td>95 (6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bloodlessness</td>
<td>0.8 (0.3)</td>
<td>4.8 (0.5)</td>
<td>1.1 (0.5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leg effort</td>
<td>1.6 (0.5)</td>
<td>5.6 (0.5)</td>
<td>3.1 (0.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

To permit comparison between different subjects, Pga data are presented as abdominal pressures (Pab) by subtracting the hydrostatic pressure gradient. 

*p<0.05, hyperinflators v euvolumnics.

†10 watt.

of 100 ml in the mean tidal volume. This difference is likely to arise from physiological rather than methodological factors. The change in Vcw tended to be larger than the volume change at the mouth and was more marked during expiration, reflecting the effect of gas compression and also the shift of blood between thoracic and extrathoracic regions.15

Our data have clinical implications. They help explain why spirometry is such a poor predictor of exercise capacity in individual COPD patients, since those with apparently better resting values can still be limited by their efforts to reduce end expiratory Vcw. Evidence from studies at rest in patients with COPD and with kyphoscoliosis16 17 suggest that the order of recruitment of the respiratory muscles during breathing is an automatic response of the central controller. This stereotyped behaviour may explain why some patients with COPD adopt a euvolumic breathing pattern during exercise. Whether previously euvolumic patients adapt to the onset of persistent tidal flow limitation and then allow Vcw to rise remains to be established. Some therapeutic interventions may work by modifying these volume related exercise responses. Thus, in healthy subjects, reducing the work of breathing can increase the oxygen consumption of the locomotor muscles,14 15 while in patients with COPD the major effect of supporting ventilation is to increase exercise duration in patients with the most marked abnormal muscle activation.16

In conclusion, exercise limitation in COPD and its attendant dyspnoea is not necessarily associated with dynamic pulmonary hyperinflation. Individuals vary in the strategy of respiratory muscle recruitment that they adopt and in the resultant change in compartmental chest wall volume. The reasons for this require further investigation, and the OEP technique may be helpful in understanding the effects of treatment on exercise performance in COPD.


Interferon gamma therapy and pulmonary fibrosis

In this double blind multinational study, 330 patients with idiopathic pulmonary fibrosis were randomly assigned to treatment with either subcutaneous interferon gamma-1b (n = 162) or placebo (n = 168) three times daily for 48 weeks. Interferon gamma-1b had no significant effect on the primary end point (disease progression or death) compared with placebo. 10% of patients died in the active treatment group compared with 17% in the placebo group (p = 0.08). The median time to death or disease progression was 439 days in the active group and 344 days in the placebo group (p = 0.50). Active treatment was not associated with any differences in gas exchange, lung function, or conventional quality of life measures. Exploratory analysis did reveal a greater effect of the active treatment in reducing mortality in patients with milder disease (parameter > median value of the group—that is, baseline forced vital capacity (FVC) >62% predicted and carbon monoxide transfer factor >35% predicted). Active treatment was associated with more frequent influenza-like symptoms and a higher incidence of pneumonia. However, respiratory infections were of equal severity and discontinuation rates were similar in the two groups.

This study failed to show any significant effect of interferon gamma-1b on disease progression, death, gas exchange, lung function, or quality of life in idiopathic pulmonary fibrosis. Exploratory analysis suggested, but could not confirm, a survival benefit for the active treatment in patients with milder disease. Due to the limited size and duration of the trial, a smaller survival benefit cannot be excluded. Further trials are required of adequate power to answer these questions.

Antiretroviral therapy improves outcome of HIV infected adults with TB

In this prospective observational cohort study from Taiwan the outcome of HIV infected TB patients and HIV infected non-TB patients treated with highly active antiretroviral therapy (HAART) was compared.

A total of 46 TB and 230 non-TB antiretroviral naive patients were included between June 1994 and October 2002. The median duration of antituberculous therapy was 9 months (range 1–24). Viral clearance (20 of 46 at week 17 of 230, RR 0.93 (95% CI 0.65 to 1.34); p = 0.701) was similar in the two groups, as was the virological failure during HAART (RR 1.49 (95% CI 0.92 to 2.41); p = 0.14). The CD4 cell count increased in both groups (71 v 64 x 10³ cells/l, p = 0.70). The risk for HIV progression to new opportunistic illnesses (adjusted RR 1.16 (95% CI 0.76 to 1.77)) and the adjusted hazard ratio for death of TB patients compared with non-TB patients was also similar in the two groups (1.18 (95% CI 0.65 to 2.32) before HAART era and 0.89 (95% CI 0.57 to 1.69) in HAART era).

This study addresses the important issue of HIV and TB co-infection and shows that TB does not alter the virological and immunological responses and the clinical outcome when these patients are treated with HAART and an appropriate antituberculous therapy. The authors do point out, however, that the rate of multidrug resistant TB was low and few of these patients were intravenous drug users or homeless, distinguishing them from some other study populations. They had access to high quality follow up and treatment. Ideally, we would like to have a situation where we could provide care of an equally high standard to all patients with HIV and TB co-infection to ensure that these results are widely applicable.

www.thoraxjnl.com
Antiretroviral therapy improves outcome of HIV infected adults with TB

G Rohde

Thorax 2004 59: 216

Updated information and services can be found at:
http://thorax.bmj.com/content/59/3/216.2

These include:

References
This article cites 1 articles, 0 of which you can access for free at:
http://thorax.bmj.com/content/59/3/216.2#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Drugs: infectious diseases (968)
HIV/AIDS (194)
Epidemiologic studies (1829)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/